AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7745785 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia alone
Number of subjects: 21
Study 7745785 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia plus epidural anesthesia
Number of subjects: 21
Study 1975198 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 12
Study 1975198 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprofylline
Number of subjects: 12
Study 1975198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7010929 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil (1200 mg daily for 3 months)
Number of subjects: 60
Study 7010929 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31479722 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab 420 mg subcutaneously, administered in-hospital and after 4 weeks, on top of atorvastatin 40 mg.
Number of subjects: 308
Study 31479722 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered in-hospital and after 4 weeks, on top of atorvastatin 40 mg.
Number of subjects: 308
Study 28689179 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 3956
Study 28689179 — intervention group
Group type: COMPARATOR
Intervention: Edoxaban
Number of subjects: 3956
Study 27901619 — intervention group
Group type: EXPERIMENTAL
Intervention: Brøset Violence Checklist (BVC) implemented in 7 intervention wards
Number of subjects: 15
Study 27901619 — intervention group
Group type: COMPARATOR
Intervention: Control wards (8 wards without BVC)
Number of subjects: 15
Study 24433264 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracutaneous suture
Number of subjects: 0
Study 24433264 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous skin stapling
Number of subjects: 0
Study 20574648 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab monotherapy
Number of subjects: 302
Study 20574648 — intervention group
Group type: COMPARATOR
Intervention: DMARDs
Number of subjects: 302
Study 20101919 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance Training (ET)
Number of subjects: 27
Study 17201546 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to a physically attractive target
Number of subjects: 6
Study 17201546 — intervention group
Group type: EXPERIMENTAL
Intervention: Body dissatisfaction
Number of subjects: 6
Study 17201546 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to attractive models and nonmodels
Number of subjects: 6
Study 17201546 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to a thin vase
Number of subjects: 6
Study 17201546 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation of body dissatisfaction
Number of subjects: 6
Study 15073451 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (Crestor) 5-40 mg
Number of subjects: 10000
Study 15073451 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10000
Study 15073451 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (Crestor) > or =96 weeks
Number of subjects: 10000
Study 11284474 — intervention group
Group type: COMPARATOR
Intervention: Current protocol (gastric residual volume threshold, 150 mL, optional prokinetic)
Number of subjects: 96
Study 11284474 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed feeding protocol (gastric residual volume threshold 250 mL, mandatory prokinetic)
Number of subjects: 96
Study 11284474 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed feeding protocol
Number of subjects: 96
Study 11284474 — intervention group
Group type: COMPARATOR
Intervention: Current protocol
Number of subjects: 96
Study 11284474 — intervention group
Group type: EXPERIMENTAL
Intervention: Both protocols
Number of subjects: 96
Study 9396172 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicobacter pylori positive patients
Number of subjects: 92
Study 9396172 — intervention group
Group type: COMPARATOR
Intervention: Helicobacter pylori negative patients
Number of subjects: 92
Study 9396172 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with normal mucosa
Number of subjects: 92
Study 9396172 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients younger than fifty
Number of subjects: 92
Study 7701793 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated blood gastrin levels in colorectal cancer patients
Number of subjects: 112
Study 7701793 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypergastrinemia incidence
Number of subjects: 112
Study 7701793 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrin concentration in elderly patients
Number of subjects: 112
Study 7701793 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative gastrinemia levels
Number of subjects: 112
Study 3548735 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplement (MaxEPA)
Number of subjects: 60
Study 3548735 — intervention group
Group type: COMPARATOR
Intervention: Olive oil
Number of subjects: 60
Study 29624537 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular temperature management
Number of subjects: 21
Study 29624537 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional cooling plus intravascular temperature management
Number of subjects: 21
Study 29624537 — intervention group
Group type: COMPARATOR
Intervention: Conventional cooling
Number of subjects: 21
Study 29624537 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional cooling and intravascular temperature management
Number of subjects: 21
Study 26725762 — intervention group
Group type: EXPERIMENTAL
Intervention: losartan/HCTZ
Number of subjects: 231
Study 26725762 — intervention group
Group type: EXPERIMENTAL
Intervention: CCB/ARB
Number of subjects: 231
Study 24868151 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbidity-adapted exercise protocols for physiological adaptations (coronary disease, heart failure, hypertension, diabetes type 2, chronic obstructive pulmonary diseases, obesity)
Number of subjects: 11
Study 24868151 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbidity-adapted exercise protocols for behavioral adaptations (chronic a-specific pain, nonspecific low back pain, depression)
Number of subjects: 11
Study 24868151 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbidity-adapted exercise protocols for environmental adaptations (visual or hearing impairments)
Number of subjects: 11
Study 23793042 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking a virtual cigarette
Number of subjects: 45
Study 23793042 — intervention group
Group type: COMPARATOR
Intervention: Throwing virtual darts
Number of subjects: 45
Study 23793042 — intervention group
Group type: COMPARATOR
Intervention: Just being in the virtual pub
Number of subjects: 45
Study 21059184 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational intervention (BMI)
Number of subjects: 677
Study 21059184 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-delivered interventions (CDIs)
Number of subjects: 677
Study 21059184 — intervention group
Group type: COMPARATOR
Intervention: Control (delayed control)
Number of subjects: 677
Study 21059184 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions (BMI and CDIs)
Number of subjects: 677
Study 17700653 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance analysis (BIA) for predicting total body water (TBW)
Number of subjects: 341
Study 17700653 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance analysis (BIA) for predicting fat‐free mass (FFM)
Number of subjects: 341
Study 17136944 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine plus beta-alanine (CA)
Number of subjects: 33
Study 17136944 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (C)
Number of subjects: 33
Study 17136944 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 33
Study 12712108 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 100 mg (twice daily)
Number of subjects: 30
Study 12712108 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac 200 mg (twice daily)
Number of subjects: 30
Study 12712108 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide 200 mg (twice daily)
Number of subjects: 30
Study 10724053 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyuria with a white blood cell count greater than 10 per microliter
Number of subjects: 761
Study 10724053 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean urine leukocyte count in patients with CAUTI
Number of subjects: 761
Study 10724053 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyuria associated with CAUTI caused by gram-negative bacilli
Number of subjects: 761
Study 10724053 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyuria associated with infections caused by coagulase-negative staphylococci and enterococci
Number of subjects: 761
Study 10724053 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyuria associated with infections caused by yeasts
Number of subjects: 761
Study 8923079 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone positioning
Number of subjects: 15
Study 8923079 — intervention group
Group type: COMPARATOR
Intervention: Supine positioning
Number of subjects: 15
Study 8923079 — intervention group
Group type: EXPERIMENTAL
Intervention: Responders (n = 9)
Number of subjects: 15
Study 8923079 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonresponders (n = 6)
Number of subjects: 15
Study 1414899 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (400 mg/day)
Number of subjects: 22
Study 1414899 — intervention group
Group type: COMPARATOR
Intervention: Mexiletine (720 mg/day)
Number of subjects: 22
Study 1414899 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall patient group
Number of subjects: 22
Study 3926135 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium aspartate (15 mmol magnesium/day)
Number of subjects: 17
Study 3926135 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 31310277 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Acetaminophen
Number of subjects: 0
Study 31310277 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29940292 — intervention group
Group type: EXPERIMENTAL
Intervention: ITACA smoking prevention education program (4-year cognitive-behavioral intervention based on the social-influences model integrated into schools' regular curricular activities)
Number of subjects: 1055
Study 27670863 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic aerobic exercise with music therapy (G1)
Number of subjects: 35
Study 27670863 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic aerobic exercise at any rhythm (G2)
Number of subjects: 35
Study 27670863 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 35
Study 25447467 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco Tactics website with nurse counseling by phone and access to nicotine replacement therapy (NRT)
Number of subjects: 145
Study 25447467 — intervention group
Group type: COMPARATOR
Intervention: 1-800-QUIT-NOW telephone line intervention
Number of subjects: 145
Study 25447467 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco Tactics website
Number of subjects: 145
Study 22344198 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate depot 11.25 mg
Number of subjects: 84
Study 22344198 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate depot 30 mg
Number of subjects: 84
Study 22344198 — intervention group
Group type: COMPARATOR
Intervention: Leuprolide acetate depot (both doses)
Number of subjects: 84
Study 20668455 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/day; n=15)
Number of subjects: 31
Study 20668455 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=16)
Number of subjects: 31
Study 17436360 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiong‐gui‐tiao‐xue‐yin at a dose of 6.0 g/day (Group X)
Number of subjects: 82
Study 17436360 — intervention group
Group type: COMPARATOR
Intervention: Ergometrine (methylergometrine maleate) at a dose of 0.375 mg/day (Group E)
Number of subjects: 82
Study 15464183 — intervention group
Group type: COMPARATOR
Intervention: No further chemotherapy (n=200)
Number of subjects: 410
Study 15464183 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard chemotherapy (n=210)
Number of subjects: 410
Study 11451592 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite skin replacement (CSR)
Number of subjects: 7
Study 11451592 — intervention group
Group type: COMPARATOR
Intervention: Split thickness autograft (Control)
Number of subjects: 7
Study 9680921 — intervention group
Group type: EXPERIMENTAL
Intervention: Gel
Number of subjects: 25
Study 9680921 — intervention group
Group type: COMPARATOR
Intervention: Margarine
Number of subjects: 25
Study 8003844 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pamidronate (APD) 30 mg as a single infusion every 3 months
Number of subjects: 32
Study 8003844 — intervention group
Group type: COMPARATOR
Intervention: Oral fluoride (20‐30 mg F/day)
Number of subjects: 32
Study 2571403 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) aqueous nasal spray
Number of subjects: 18
Study 2571403 — intervention group
Group type: COMPARATOR
Intervention: Terfenadine tablets
Number of subjects: 18
Study 1105726 — intervention group
Group type: EXPERIMENTAL
Intervention: New method for objective assessment of cough
Number of subjects: 18
Study 1105726 — intervention group
Group type: EXPERIMENTAL
Intervention: Double blind crossover trial
Number of subjects: 18
Study 31802129 — intervention group
Group type: EXPERIMENTAL
Intervention: Insomnia symptoms
Number of subjects: 0
Study 31802129 — intervention group
Group type: EXPERIMENTAL
Intervention: Oversleeping
Number of subjects: 0
Study 31802129 — intervention group
Group type: EXPERIMENTAL
Intervention: Undersleeping
Number of subjects: 0
Study 31802129 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous sleep duration
Number of subjects: 0
Study 31802129 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime sleepiness
Number of subjects: 0
Study 31802129 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronotype
Number of subjects: 0
Study 29697450 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression Modeling (RM)
Number of subjects: 207
Study 29697450 — intervention group
Group type: COMPARATOR
Intervention: Historical Mean (HM)
Number of subjects: 207
Study 28880972 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA-5T4
Number of subjects: 55
Study 28880972 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of MVA-5T4 and cyclophosphamide
Number of subjects: 55
Study 28880972 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 55
Study 28880972 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 55
Study 26296452 — intervention group
Group type: EXPERIMENTAL
Intervention: Low energy diet (LED, 800‐1,000 kcal/day)
Number of subjects: 70
Study 26296452 — intervention group
Group type: COMPARATOR
Intervention: Aerobic interval training (AIT)
Number of subjects: 70
Study 23844569 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Interactive Diary (DID)
Number of subjects: 127
Study 23844569 — intervention group
Group type: COMPARATOR
Intervention: Traditional education (Control)
Number of subjects: 127
Study 21828301 — intervention group
Group type: EXPERIMENTAL
Intervention: Questioning during lectures (experimental lectures with questions asked throughout)
Number of subjects: 23
Study 21828301 — intervention group
Group type: COMPARATOR
Intervention: Traditional lecturing methods (control lectures)
Number of subjects: 23
Study 21828301 — intervention group
Group type: EXPERIMENTAL
Intervention: Questioning during lectures
Number of subjects: 23
Study 19576065 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: traditional superior corneal incision phacoemulsification surgery and AcrySof SN60AT IOL implantation
Number of subjects: 90
Study 19576065 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: corneal topography guiding incision phacoemulsification surgery and AcrySof SN60AT IOL implantation
Number of subjects: 90
Study 19576065 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C: corneal topography guiding incision phacoemulsification surgery and AcrySof SN60WF IOL implantation
Number of subjects: 90
Study 17094524 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg cisatracurium [2ED95]
Number of subjects: 60
Study 17094524 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg rocuronium [2ED95]
Number of subjects: 60
Study 17094524 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 0.075 mg/kg cisatracurium [1ED95] plus 0.3 mg rocuronium [1ED95]
Number of subjects: 60
Study 16242695 — intervention group
Group type: EXPERIMENTAL
Intervention: Pubovaginal sling
Number of subjects: 92
Study 16242695 — intervention group
Group type: COMPARATOR
Intervention: Tension-free vaginal tape
Number of subjects: 92
Study 16242695 — intervention group
Group type: COMPARATOR
Intervention: Burch colposuspension
Number of subjects: 92
Study 12138980 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% alcoholic chlorhexidine gluconate
Number of subjects: 215
Study 12138980 — intervention group
Group type: COMPARATOR
Intervention: 2% alcoholic tincture of iodine
Number of subjects: 215
Study 9921571 — intervention group
Group type: EXPERIMENTAL
Intervention: One injection of 1.6 ml (480 mcg) of G-CSF
Number of subjects: 76
Study 9921571 — intervention group
Group type: COMPARATOR
Intervention: Two injections of 0.8 ml each of G-CSF
Number of subjects: 76
Study 7476576 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoionic contrast medium (sodium/‐meglumine ioxaglate, Hexabrix)
Number of subjects: 20
Study 7476576 — intervention group
Group type: COMPARATOR
Intervention: Non-ionic contrast medium (iopromide, Ultravist 300)
Number of subjects: 20
Study 2280237 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 11
Study 2280237 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 11
Study 2280237 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 11
Study 574098 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1.7 g/day)
Number of subjects: 22
Study 574098 — intervention group
Group type: COMPARATOR
Intervention: Clofibrate (2 g/day)
Number of subjects: 22
Study 574098 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (Metformin + Clofibrate)
Number of subjects: 22
Study 31735410 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute-phase cognitive therapy (A-CT)
Number of subjects: 764
Study 31735410 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation-phase treatment (CCT)
Number of subjects: 764
Study 31735410 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 764
Study 31735410 — intervention group
Group type: COMPARATOR
Intervention: Matched pill placebo
Number of subjects: 764
Study 31153781 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hydrocortisone (HC) 100mg every eight hours until the second postoperative day
Number of subjects: 40
Study 31153781 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 27916987 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-week very-low-calorie diet (500 kcal per day)
Number of subjects: 61
Study 27916987 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week low-calorie diet (1250 kcal per day)
Number of subjects: 61
Study 27916987 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight stable diet (WS period)
Number of subjects: 61
Study 27916987 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss (WL) period
Number of subjects: 61
Study 26529011 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-Vitamin/Mineral (MVM) supplementation
Number of subjects: 58
Study 26529011 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 23363495 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional dose of IPV (one fifth of a full dose) administered intradermally
Number of subjects: 310
Study 23363495 — intervention group
Group type: COMPARATOR
Intervention: Full dose of IPV administered intramuscularly
Number of subjects: 310
Study 21208748 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 36
Study 21208748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 19954721 — intervention group
Group type: EXPERIMENTAL
Intervention: HFR (Hemodiafiltration with on-line endogenous reinfusion)
Number of subjects: 11
Study 19954721 — intervention group
Group type: COMPARATOR
Intervention: LHD (Conventional low flux hemodialysis)
Number of subjects: 11
Study 17359208 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia for dental extraction
Number of subjects: 201
Study 14722327 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg/day for 3 days)
Number of subjects: 12
Study 14722327 — intervention group
Group type: COMPARATOR
Intervention: MDMA (100 mg)
Number of subjects: 12
Study 11476796 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous hCG (5,000 IU)
Number of subjects: 28
Study 11476796 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular hCG (5,000 IU)
Number of subjects: 28
Study 11476796 — intervention group
Group type: EXPERIMENTAL
Intervention: Both subcutaneous and intramuscular hCG
Number of subjects: 28
Study 9570254 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin (750 mg b.d.)
Number of subjects: 150
Study 9570254 — intervention group
Group type: COMPARATOR
Intervention: Intravenous cephazolin (1 g b.d.)
Number of subjects: 150
Study 8047707 — intervention group
Group type: EXPERIMENTAL
Intervention: Rockport Fitness Walking Test (RFWT)
Number of subjects: 0
Study 8047707 — intervention group
Group type: EXPERIMENTAL
Intervention: New prediction equations derived from RFWT variables
Number of subjects: 0
Study 8047707 — intervention group
Group type: COMPARATOR
Intervention: Kline, Porcari, Hintermeister equations (1987)
Number of subjects: 0
Study 2925842 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine A (CsA)
Number of subjects: 0
Study 2925842 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine A + Prednisone (CsA + P)
Number of subjects: 0
Study 2925842 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2925842 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine A (CsA) and Cyclosporine A + Prednisone (CsA + P)
Number of subjects: 0